For patients on blood thinners, the line between preventing a stroke and risking a fatal bleed is perilously thin. The standard of care, while life-saving, carries a significant burden: a constant calculation of risk, dietary restrictions, and the looming threat of uncontrolled bleeding from a fall or injury. A new preclinical biotech from North Carolina is betting that a therapeutic built from folded RNA, not a small molecule, can offer a more precise and immediately reversible form of anticoagulation.
Helixomer Inc., founded in 2020 by two NC State University researchers, is developing what it calls a chemically modified RNA origami (RNAO) platform. The technology uses strands of RNA engineered to fold into specific three-dimensional nanostructures. These structures can be studded with aptamers, short nucleic acid sequences that bind to specific targets like proteins. For its lead program, Helixomer is targeting thrombin, a central enzyme in the blood-clotting cascade [NC State MSE, Dec 2023]. The company's ambition is to create a system: one RNA origami molecule (HEX01) that inhibits thrombin to prevent clotting, and a second, complementary molecule (HEX02) designed to rapidly neutralize the first [PubMed 38720458].
The RNA Origami Platform Wedge
Helixomer's scientific premise rests on structural control. Traditional small-molecule drugs or even single aptamers interact with their targets in a one-to-one, often transient manner. By using RNA origami as a scaffold, the company aims to place multiple aptamers in a precise spatial arrangement on a single, stable nanostructure. This multivalent binding is theorized to create a stronger, more specific interaction with the target protein, potentially boosting efficacy while reducing off-target effects. The platform's core claim is that these designer nucleic acid structures are also non-immunogenic, a critical hurdle for any biologic therapeutic [Helixomer.com/technology]. The $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health, awarded in late 2023, is funding the advancement of this paired anticoagulant and reversal agent system from academic concept toward investigational new drug (IND)-enabling studies [NC State MSE, Dec 2023].
Preclinical Proof in Plasma and Mice
The company's most compelling data to date, published in a peer-reviewed journal in May 2024, demonstrates functional activity in controlled settings. Researchers reported that the lead RNA origami candidate, HEX01, acted as a direct thrombin inhibitor. More notably, its designed reversal agent, HEX02, was shown to neutralize HEX01's anticoagulant activity in human plasma within 30 seconds in vitro. In a murine model of liver laceration, a scenario meant to simulate traumatic bleeding, the administration of HEX02 after HEX01 effectively restored hemostasis [PubMed 38720458][NC State MSE, Jul 2024]. These early results provide a foundational proof-of-concept for the platform's central thesis: a fast-acting, specific reversal mechanism.
The Team and the Translation Challenge
Helixomer's origins are deeply academic, which frames both its strength and its primary risk. The co-founders bring specialized technical expertise to the daunting task of drug development.
| Co-Founder | Role & Background |
|---|---|
| Thom LaBean | Co-founder, NC State Professor of Materials Science and Engineering. Expert in biomolecular design and nucleic acid nanotechnology [NC State MSE, Dec 2023]. |
| Abhichart Krissanaprasit | Co-founder, listed as an expert in biomolecular engineering. Co-author on the key 2024 publication [PubMed 38720458][LinkedIn Abhichart Krissanaprasit]. |
This foundation in basic science is a clear asset for navigating the complex biophysics of RNA nanostructures. The path from a university lab to a clinical-stage biotech, however, is fraught with translational challenges that extend beyond elegant science. The company's current funding is entirely non-dilutive government grant money, a common and prudent start for deep tech ventures but a fraction of the capital required to shepherd a therapeutic through clinical trials. The absence of disclosed venture capital backing or industry partnerships at this stage signals that the commercial and operational build-out likely remains ahead.
Navigating a Crowded Therapeutic Landscape
The anticoagulation market is vast, established, and competitive. Helixomer is not merely proposing a new drug; it is proposing a new drug modality (RNA nanostructures) for a condition with entrenched standards of care. The risks here are multifaceted and significant.
- Clinical precedent. RNA-based therapeutics have achieved historic successes (e.g., mRNA vaccines, siRNA drugs), but an RNA origami drug represents a novel and unproven structural approach in humans. The regulatory pathway for such a complex biologic will require extensive characterization and safety data.
- Development capital. The $2 million NIH grant is substantial for early research but is a rounding error compared to the hundreds of millions typically required to fund a drug through Phase 3 trials. Securing Series A venture funding will be a critical, non-negotiable milestone.
- Commercial displacement. Anticoagulants like warfarin, direct oral anticoagulants (DOACs), and heparin have decades of clinical use and well-understood profiles. Reversal agents for some DOACs already exist. Convincing clinicians to adopt a completely new system will require demonstrating a dramatic improvement in safety, speed of reversal, or patient population not served by current options.
The company's near-term focus will rightly be on using its NIH funding to generate robust preclinical data packages to de-risk the platform for future investors and potential pharmaceutical partners. The next twelve months should reveal whether Helixomer can transition from an academically interesting project to a venture-scale biotechnology company.
For patients requiring anticoagulation therapy, particularly those in surgical or trauma settings where bleeding risk is acute, the standard of care involves a careful balancing act. Doctors manage this with a combination of drugs, frequent blood monitoring, and reversal agents that can be slow, expensive, or incomplete. Helixomer's bet is that its precisely engineered RNA nanostructures can offer a more controllable switch: turning anticoagulation on and off with speed and specificity that small molecules cannot match. It is a high-science, high-risk endeavor, aiming not just to join the market, but to redefine a core parameter of care for a vulnerable population.
Sources
- [NC State MSE, Dec 2023] MSE Startup Helixomer Receives $2M NIH Grant to Advance Breakthrough Anticoagulant and Reversal Agent | https://mse.ncsu.edu/2023/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/
- [Helixomer.com] Technology | https://www.helixomer.com/technology
- [PubMed, 2024] A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model | https://pubmed.ncbi.nlm.nih.gov/38720458/
- [SBIR.gov] Helixomer, Inc. | https://www.sbir.gov/portfolio/2098455
- [NC State MSE, Jul 2024] New Blood Thinner Reversal Agent Shows Promise in Early Tests | https://mse.ncsu.edu/2024/07/new-blood-thinner-reversal-agent-shows-promise-in-early-tests/
- [LinkedIn] Abhichart Krissanaprasit | https://www.linkedin.com/posts/abhichart-krissanaprasit-90779511b_excited-to-share-our-works-hopefully-our-activity-7077399529334980608-3QE7